A Phase II Study of Neoadjuvant Bio-chemotherapy With Cetuximab, Paclitaxel, and Cisplatin (CPC) Followed by Cetuximab-based Concurrent Bio-radiotherapy in High-risk Locally Advanced Oral Squamous Cell Carcinoma (OSCC)
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 47
- 试验地点
- 1
- 主要终点
- The primary endpoint is the overall response rate after completion of the assigned treatment.
研究概览
简要总结
Surgical resection followed by concurrent chemoradiotherapy is considered as the standard of care for locally advanced OSCC (LAOSCC). Although the treatment could provide prompt local control, but it is also associated with high incidence of distant failure. Systemic chemotherapy given either before (neoadjuvant) or after (adjuvant) definitive local treatment has been extensively evaluated to improve the clinical outcome in LAOSCC. Regimens of taxane/cisplatin-based combinations have been shown to improve the treatment outcome of patients with locally advanced head and neck squamous cell carcinoma (HNSCC) in neoadjuvant setting. Recently, cetuximab (Erbitux®), a monoclonal antibody against epidermal growth factor receptor (EGFR), has also been proven to be an efficient agent for advanced and/or refractory HNSCC with acceptable toxicity profiles. In current study, we shall evaluate the feasibility, efficacy and safety of a triplet bio-chemotherapy consisting of cetuximab, paclitaxel, and cisplatin followed by cetuximab-based concurrent bio-radiotherapy (CBRT) in patients with LAOSCC.
详细描述
Patients with high-risk, locally advanced (TxN2b~3 or T4N0~3, M0) OSCC will be eligible. To detect an interested objective response rate (p1) of 80% versus a non-interested response (p0) rate of 60%, with an α and 1-β of 0.05 and 0.2, respectively (two-sided test), including the estimated dropout rate of 10%, a total of 47 patients will be recruited.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •High-risk, locally advanced (TxN2b~3 or unresectable T4, M0) OSCC
- •Histologically confirmed squamous cell carcinoma
- •Performance status: Eastern Cooperative Oncology Group performance status (ECOG) 0-1
- •age 18 years or older, less than 70 years of age
- •Having signed informed consent
- •Measurable disease by CT or MRI
- •Adequate hematologic, hepatic and renal function
排除标准
- •Prior radiotherapy for targeted lesions, chemotherapy, EGFR pathway targeting therapy
- •Prior surgery for cancer except for the purpose of diagnostic biopsy
- •Concomitant active 2nd malignancies or disease-free of malignancies < 3 years before the study except adequately treated in situ cervical cancer, or non-melanoma skin cancer
- •Concomitant anticancer therapies within the past 28 days
- •Severe cardiopulmonary diseases and other systemic disease under poor control
- •Uncontrolled chronic neuropathy
- •Women who are positive of pregnancy, or in breast-feeding
- •Known allergy to any study treatment
- •Legal incapacity
- •Significant disease which, in the investigator's opinion, would exclude the patient from the study
研究组 & 干预措施
open label
an open-labelled, single-arm
干预措施: Cetuximab,Paclitaxel,Cisplatin (Drug)
结局指标
主要结局
The primary endpoint is the overall response rate after completion of the assigned treatment.
时间窗: 18 weeks
次要结局
- Secondary endpoints include the response rate after neoadjuvant therapy, progression-free survival, overall survival, biomarker prediction, and toxicity.(>2 years)